ストックスクリーナーアプリを入手
0.2781
13.97%
-0.0452
前日終値:
$0.3233
開ける：
$0.32
24時間の取引高:
5.90M
Relative Volume:
10.55
時価総額：
$22.23M
収益：
-
当期純損益:
$-60.61M
株価収益率:
-0.4635
EPS:
-0.6
ネットキャッシュフロー:
$-22.91M
1週間 パフォーマンス:
-41.52%
1か月 パフォーマンス:
-38.23%
6か月 パフォーマンス:
-55.15%
1年 パフォーマンス:
-81.70%
1日の値動き範囲:
$0.2612
$0.3233
1週間の範囲:
$0.2612
$0.565
52週間の値動き範囲:
$0.2612
$1.89
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
BLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BLRX | 0.2781 | 22.23M | 0 | -60.61M | -22.91M | -0.60 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-05-18 | アップグレード | Maxim Group | Hold → Buy |
| 2017-02-13 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-08-17 | 繰り返されました | Maxim Group | Buy |
| 2015-07-27 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Bioline Rx Ltd Adr (BLRX) 最新ニュース
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex
BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle
Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks
Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks
Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex
There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News
Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News
BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle
Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com
What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register
Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News
Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex
BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India
Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily
Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India
Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com
BioLineRx Q1 Success with APHEXDA® Growth - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News
BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks
BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com
Examining Bioline Rx Ltd ADR (BLRX) more closely is necessary – US Post News - US Post News
BioLineRx Showcases Promising Cancer Drug Trial Results - TipRanks
Bioline Rx Ltd Adr (BLRX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):